Structure of oral PI3K_-selective kinase inhibitor prodrug PF-06843195

oral PI3K_-selective kinase inhibitor prodrug

preclinical candidate for breast cancer

from mining of prior PI3K inh., SBDD, and opt.

J. Med. Chem., Dec. 24, 2020

Pfizer, San Diego, CA

Pfizer oral PI3ka-selective kinase inhibitor prodrug


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.